ClinicalTrials.gg
CompletedNCT04320342TRITONUpdated Sep 21, 2026

A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

A Phase 3 interventional study of Beclomethasone Dipropionate and Glycopyrronium Bromide in COPD and COPD Exacerbation, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 436 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,406
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
4th of 73
3,406 · median 152
Started
2022
the only one that year
Phase 3
33 of 73
1 open now
Registered
63rd of 73
by date
Lead sponsor
13 of 73
Chiesi Farmaceutici S.p.A.

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 4th largest by enrollment, is the only one that started in 2022, is one of 33 in phase 3, and was the 63rd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.

Read the detailed description

This is a phase III, multinational, multicenter, randomized, double-blind active controlled 2-arm parallel group study to compare efficacy, safety, and tolerability of CHF 5993 pMDI with CHF 1535 pMDI with respect to lung function, incidence of moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes.

After screening, eligible subjects will enter 2-week run-in period using their regular COPD maintenance therapies after which they will be randomized to one of 2 study treatment groups. Following randomization, subjects will be assessed after 4 weeks then at 6-week intervals thereafter for a period of 52 weeks. A follow-up safety phone call will be performed a week after the last clinic visit. A subset of subjects consenting to participate in the pharmacokinetic substudy will undergo additional assessments (totaling 3 visits) during the scheduled study visits.

During the study, daily symptoms, rescue medication use and compliance with the study drug will be recorded via a subject electronic diary. Subject concomitant medications, adverse events, and healthcare resource utilization will be assessed and recorded throughout the study. At intermittent study visits, subjects will undergo vital signs examinations including weight, spirometry measurements, and 12-lead ECG. Symptoms and COPD health status will be assessed through disease specific questionnaires. Routine hematology, blood chemistry, and serum pregnancy testing will be performed before enrollment and at end of study.

03

Conditions studied

  • COPD
  • COPD Exacerbation

Keywords

  • Lung Function
  • Safety Profile
  • Beclomethasone Dipropionate
  • Glycopyrronium Bromide
  • Formoterol Fumarate
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written must be obtained prior to initiating any study-related procedures
  • Outpatient
  • Male or female subjects aged ≥40 years
  • Female subjects:

    1. fulfilling one of the following criteria: i. WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective method from the signing of the informed consent form and until the follow-up contact or ii. WOCBP with non-fertile male partners (contraception is not required in this case).
    2. Female subjects of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. or permanently sterile as per definitions given in Appendix 5). Tubal ligation or partial surgical interventions are not acceptable. If indicated, as per investigator's request, post-menopausal status may be confirmed by follicle-stimulating hormone levels (according to local laboratory ranges)
  • diagnosis for at least 12 months before the screening visit in accordance with the definition by the GOLD 2020 Report
  • Current or ex-smokers who quit smoking at least 6 months prior to screening with a smoking history of at least 10 pack-years [pack-years = (number of cigarettes per day x number of years)/20]
  • COPD Assessment Test (CAT) score ≥10
  • A pre- and post-bronchodilator /FVC ratio \<0.70 at screening
  • A post-bronchodilator FEV1 \<50% predicted normal at screening and a documented history of ≥1 moderate or severe COPD exacerbation in the previous 12 months OR a post-bronchodilator FEV1 ≥50% and \<80% of predicted normal at screening and a documented history of ≥2 moderate COPD exacerbations or ≥1 severe COPD exacerbation in the previous 12 months
  • Subjects receiving daily inhaled maintenance therapy for their COPD, at a stable dose for at least 3 months prior to the screening and randomization visits
  • Documentation (including imagery and report) of chest x-ray (CXR) or CT scan performed within 6 months prior to the screening visit, without evidence of significant abnormalities (other than those related to the presence of COPD).
  • A cooperative attitude and ability to demonstrate correct use of the pMDI inhalers and eDiary.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant (as evident by a positive urine hCG or serum β-hCG test) or lactating
  • Subjects using the following medications prior to the screening visit and during the run-in period:

    1. Systemic/oral/parenteral in the prior 4 weeks
    2. Use of antibiotics for a lower respiratory tract infection (e.g. pneumonia) or exacerbation in the prior 4 weeks
    3. Any long-term chronic maintenance use of antibiotic treatment in the prior 4 weeks
    4. Oral xanthine derivatives (e.g. theophylline) in the prior 7 days
  • A moderate or severe COPD exacerbation or a respiratory tract infection (e.g., pneumonia) that has not resolved ≤14 days prior to the screening visit or during the run-in period
  • Current treatment with non-cardioselective β-blockers
  • Requirement of long term (> 15 hours daily) oxygen therapy
  • Known respiratory disorders other than COPD which may impact the efficacy of the study drug according to investigator's judgement.
  • Lung transplant surgery or lung volume reduction surgery (subjects with lung volume reduction surgery are excluded if the procedure was performed within 1 year before the Screening visit)
  • Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the investigator, would prevent use of anticholinergic agents
  • History of to M3 receptor antagonists, β2 agonists, corticosteroids or any of the contained in any of the study drugs used in the trial which may raise or impact the efficacy of the study drug according to the investigator's judgement
  • Subject has severe, acute or uncontrolled cardiovascular condition (such as but not limited to unstable ischemic heart disease, Class IV, left ventricular failure, acute myocardial infarction or unstable angina) in the last 6 months
  • An abnormal and 12-lead at either the screening or randomization visit. This is characterized as but not limited to any of the following findings:

    1. Atrial fibrillation (AF) with rapid ventricular response > 120 bpm
    2. Ventricular tachycardias (sustained, non-sustained [>3 up to 30 sec])
    3. Evidence of Mobitz Type II second degree or third-degree atrioventricular block
    4. Prolonged (>450ms for males, or >470ms for females). This criterion is not applicable for subjects with a pacemaker or permanent AF.
  • Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may impact the efficacy or the safety of the study drug according to investigator's judgement
  • Unstable or uncontrolled concurrent disease which may impact the efficacy or safety of the study drug or the subject's participation in the study according to investigator's judgment
  • that has not been in complete remission for at least 1 year or any untreated localized carcinomas
  • History of alcohol abuse and/or substance/drug abuse within 12 months prior to the screening visit
  • Receipt of any other drug within 1 month or 5 half-lives (whichever is greater) prior to the screening visit or have been previously randomized in this trial, or are currently participating in another clinical trial
  • Currently in the acute phase of a pulmonary rehabilitation program within 4 weeks before the screening visit or planning to enroll in the acute phase of such a program during the study. Subjects who are in the maintenance phase of a pulmonary rehabilitation program are not excluded
  • Mentally or legally incapacitated, or subjects incarcerated as a result of an official or judicial order
  • Major surgery in the 3 months prior to the screening visit or have a planned surgery during the trial
  • Non-satisfactory compliance with the eDiary (\<65% or >135%) during the run-in period
  • Subjects requiring the use of spacer device or nebulizer for administration of maintenance COPD therapies.
  • Veins unsuitable for repeat venipuncture
  • Blood donation or blood loss (≥450mL) in the 4 weeks before randomization
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,406 participants (actual)

Study arms

  • Experimental
    BDP/FF/GB - CHF 5993

    Two inhalations twice daily of BDP/FF/GB (100/6/12.5μg) for a period of 52 weeks via pressurized metered dose inhaler

    Drug: Beclomethasone Dipropionate · Drug: Glycopyrronium Bromide · Drug: Formoterol Fumarate

  • Active comparator
    BDP/FF - CHF 1535

    Two inhalations twice daily of BDP/FF (100/6μg) for a period of 52 weeks via pressurized metered dose inhaler

    Drug: Beclomethasone Dipropionate · Drug: Formoterol Fumarate

Interventions

  • Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

    Also known as: BDP

  • Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg

    Also known as: glycopyrrolate, GB

  • Available in pressurized inhalation solution BDP/FF/GB 100/6/12.5μg and BDP/FF 100/6μg

    Also known as: FF

06

What researchers measure

Primary outcomes

  1. Change from baseline in pre-dose morning Forced Expiratory Volume in the 1st second (FEV1) at Week 28

    Time frame: Week 28

Secondary outcomes

  1. Change from baseline in 2-hour post-dose morning FEV1 at Week 28

    Time frame: Week 28

  2. Rate of moderate and severe COPD exacerbations over 52 weeks of treatment

    Annualized rate of moderate and severe COPD exacerbations as observed during the 52-week study treatment period.

    Time frame: 52-week treatment period

  3. Change from baseline in pre-dose morning FEV1 at designated clinic visits

    Time frame: Week 4, Week 10, Week 40, & Week 52

  4. Change from baseline in 2-hour post-dose morning FEV1 designated clinic visits

    Time frame: Day 1, Week 4, Week 10, Week 40, & Week 52

  5. Change from pre-dose to 2-hour post-dose morning FEV1 at designated clinic visits

    Time frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52

  6. FEV1 response (change from baseline in pre-dose morning FEV1 ≥100ml) at designated clinic visits

    Time frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52

  7. Time to first moderate or severe COPD exacerbation

    Time frame: 52-week treatment period

  8. Rate of severe COPD exacerbations over 52 weeks of treatment

    Annualized rate of severe COPD exacerbations as observed during 52-week treatment period

    Time frame: 52-week treatment period

  9. Time to first severe COPD exacerbation

    Time frame: 52-week treatment period

  10. Saint George's Respiratory Questionnaire (SGRQ) response (a decrease from baseline in total score ≥4) at designated clinic visits

    Time frame: Week 4, Week 10, Week 28, Week 40, & Week 52

  11. Change from baseline in the SGRQ total score and domain scores at each designated clinic visit

    Time frame: Week 4, Week 10, Week 28, Week 40, & Week 52

  12. Change from baseline to each inter-visit period in the percentage of days without intake of rescue medication

    Change from baseline (defined as the 2-week run-in period prior to randomization) to each inter-visit period (defined as the period of time between designated clinic visits) in percentage of days without rescue medication

    Time frame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52

  13. Change from baseline to each inter-visit period in the average use of rescue medication (number of puffs/day)

    Change from baseline (defined as the 2-week run-in period prior to randomization) in the average number of puffs per day of rescue medication for each inter-visit period (defined as the period of time between designated clinic visits).

    Time frame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52

  14. Change from baseline in pre-dose morning Forced Vital Capacity (FVC) at designated clinic visits

    Time frame: Week 4, Week 10, Week 28, Week 40, & Week 52

  15. Change from baseline in 2-hour post-dose morning FVC at designated clinic visits

    Change from baseline (defined as the pre-dose value on Day 1) in 2-hour post-dose morning FVC at designated clinic visits

    Time frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52

  16. Change from pre-dose to 2-hour post-dose morning FVC at designated clinic visits

    Time frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52

  17. Change from baseline to each inter-visit period in the average E-RS total score and domain scores

    Change from baseline (defined as the 2-week run-in period prior to randomization) in the average E-RS total score and E-RS domain scores for the period of time between designated clinic visits.

    Time frame: Day 1-Week 4, Week 4-Week 10, Week 10-Week 28, Week 28-Week 40, Week 40-Week 52

  18. Change from baseline in COPD Assessment Test (CAT) score at designated clinic visit

    The CAT is composed of 8 questions to measure the impact of COPD on daily life, which are scored from 0 to 5 with higher scores reflecting greater impact.

    Time frame: Week 4, Week 10, Week 28, Week 40, & Week 52

  19. CAT response (decrease from baseline ≥2 points) at designated clinic visits

    Time frame: Week 4, Week 10, Week 28, Week 40, & Week 52

  20. Modified Medical Research Council (mMRC) dyspnea scale at designated clinic visits

    Descriptive statistics of the mMRC dyspnea scale score at designated clinic visits. The mMRC dyspnea scale is graded from 0 to 4, with higher grades reflecting greater severity.

    Time frame: Day 1, Week 4, Week 10, Week 28, Week 40, & Week 52

  21. Change from baseline in health-related quality of life (decrease from baseline in total SGRQ score ≥4) over 52 weeks of treatment.

    Time frame: 52-week treatment period

07

Study locations

436 sites
  • Chiesi Clinical Trial Site 840350
    Birmingham, Alabama 35215-7502, United States
  • Chiesi Clinical Trial Site 840186
    Dothan, Alabama 36303, United States
  • Chiesi Clinical Trial Site 840258
    Foley, Alabama 36535, United States
  • Chiesi Clinical Trial Site 840279
    Jasper, Alabama 35501, United States
  • Chiesi Clinical Trial Site 840433
    Mobile, Alabama 36608, United States
  • Chiesi Clinical Trial Site 840206
    Montgomery, Alabama 36106, United States
  • Chiesi Clinical Trial Site 840249
    Muscle Shoals, Alabama 35661, United States
  • Chiesi Clinical Trial Site 840406
    Chandler, Arizona 85224, United States
  • Chiesi Clinical Trial Site 840402
    Peoria, Arizona 85381, United States
  • Chiesi Clinical Trial Site 840349
    Tucson, Arizona 85741, United States
  • Chiesi Clinical Trial Site 840404
    Covina, California 91723, United States
  • Chiesi Clinical Trial Site 840209
    Escondido, California 92025, United States
  • Chiesi Clinical Trial Site 840427
    La Palma, California 90623, United States
  • Chiesi Clinical Trial Site 840358
    Lomita, California 90717, United States
  • Chiesi Clinical Trial Site 840173
    Newport Beach, California 92663, United States
  • Chiesi Clinical Trial Site 840208
    Northridge, California 91324, United States
  • Chiesi Clinical Trial Site 840277
    Northridge, California 91324, United States
  • Chiesi Clinical Trial Site 840364
    Redding, California 96001, United States
  • Chiesi Clinical Trial Site 840226
    Sacramento, California 95821, United States
  • Chiesi Clinical Trial Site 840405
    Sacramento, California 95823, United States
  • Chiesi Clinical Trial Site 840107
    San Diego, California 92120, United States
  • Chiesi Clinical Trial Site 840373
    Santa Ana, California 92705, United States
  • Chiesi Clinical Trial Site 840164
    Upland, California 91786, United States
  • Chiesi Clinical Trial Site 840174
    West Covina, California 91790, United States
  • Chiesi Clinical Trial Site 840144
    Westminster, California 92683, United States
  • Chiesi Clinical Trial Site 840441
    Aurora, Colorado 80014, United States
  • Chiesi Clinical Trial Site 840229
    Boulder, Colorado 80302, United States
  • Chiesi Clinical Trial Site 840399
    Norwalk, Connecticut 06586, United States
  • Chiesi Clinical Trial Site 840116
    Altamonte Springs, Florida 32701, United States
  • Chiesi Clinical Trial Site 840268
    Aventura, Florida 33180, United States
  • Chiesi Clinical Trial Site 840192
    Brandon, Florida 33511, United States
  • Chiesi Clinical Trial Site 840310
    Brooksville, Florida 34613, United States
  • Chiesi Clinical Trial Site 840240
    Chiefland, Florida 32626, United States
  • Chiesi Clinical Trial Site 840153
    Clearwater, Florida 33756, United States
  • Chiesi Clinical Trial Site 840272
    Coral Gables, Florida 33134, United States
  • Chiesi Clinical Trial Site 840304
    Coral Gables, Florida 33134, United States
  • Chiesi Clinical Trial Site 840193
    Cutler Bay, Florida 33157, United States
  • Chiesi Clinical Trial Site 840311
    Cutler Bay, Florida 33189, United States
  • Chiesi Clinical Trial Site 840335
    Cutler Bay, Florida 33189, United States
  • Chiesi Clinical Trial Site 840141
    Daytona Beach, Florida 32117, United States
  • Chiesi Clinical Trial Site 840133
    DeLand, Florida 32720, United States
  • Chiesi Clinical Trial Site 840269
    Doral, Florida 33122, United States
  • Chiesi Clinical Trial Site 840303
    Hialeah, Florida 33010, United States
  • Chiesi Clinical Trial Site 840163
    Hialeah, Florida 33012, United States
  • Chiesi Clinical Trial Site 840165
    Hialeah, Florida 33012, United States
  • Chiesi Clinical Trial Site 840238
    Hialeah, Florida 33012, United States
  • Chiesi Clinical Trial Site 840265
    Hialeah, Florida 33012, United States
  • Chiesi Clinical Trial Site 840241
    Hialeah, Florida 33015, United States
  • Chiesi Clinical Trial Site 840253
    Hialeah, Florida 33015, United States
  • Chiesi Clinical Trial Site 840184
    Hialeah, Florida 33016, United States
  • Chiesi Clinical Trial Site 840267
    Hialeah, Florida 33016, United States
  • Chiesi Clinical Trial Site 840354
    Hialeah Gardens, Florida 33016, United States
  • Chiesi Clinical Trial Site 840256
    Hialeah Gardens, Florida 33066, United States
  • Chiesi Clinical Trial Site 840200
    Kissimmee, Florida 34741, United States
  • Chiesi Clinical Trial Site 840232
    Lakeland, Florida 33803, United States
  • Chiesi Clinical Trial Site 840113
    Leesburg, Florida 34748, United States
  • Chiesi Clinical Trial Site 840372
    Miami, Florida 33122, United States
  • Chiesi Clinical Trial Site 840137
    Miami, Florida 33125, United States
  • Chiesi Clinical Trial Site 840289
    Miami, Florida 33125, United States
  • Chiesi Clinical Trial Site 840377
    Miami, Florida 33125, United States
  • Chiesi Clinical Trial Site 840387
    Miami, Florida 33125, United States
  • Chiesi Clinical Trial Site 840326
    Miami, Florida 33126, United States
  • Chiesi Clinical Trial Site 840175
    Miami, Florida 33133, United States
  • Chiesi Clinical Trial Site 840346
    Miami, Florida 33133, United States
  • Chiesi Clinical Trial Site 840347
    Miami, Florida 33134, United States
  • Chiesi Clinical Trial Site 840205
    Miami, Florida 33135, United States
  • Chiesi Clinical Trial Site 840247
    Miami, Florida 33135, United States
  • Chiesi Clinical Trial Site 840341
    Miami, Florida 33135, United States
  • Chiesi Clinical Trial Site 840148
    Miami, Florida 33144, United States
  • Chiesi Clinical Trial Site 840239
    Miami, Florida 33144, United States
  • Chiesi Clinical Trial Site 840312
    Miami, Florida 33144, United States
  • Chiesi Clinical Trial Site 840355
    Miami, Florida 33144, United States
  • Chiesi Clinical Trial Site 840388
    Miami, Florida 33144, United States
  • Chiesi Clinical Trial Site 840237
    Miami, Florida 33155, United States
  • Chiesi Clinical Trial Site 840261
    Miami, Florida 33155, United States
  • Chiesi Clinical Trial Site 840262
    Miami, Florida 33155, United States
  • Chiesi Clinical Trial Site 840280
    Miami, Florida 33155, United States
  • Chiesi Clinical Trial Site 840178
    Miami, Florida 33165, United States
  • Chiesi Clinical Trial Site 840292
    Miami, Florida 33165, United States
  • Chiesi Clinical Trial Site 840202
    Miami, Florida 33166, United States
  • Chiesi Clinical Trial Site 840275
    Miami, Florida 33169, United States
  • Chiesi Clinical Trial Site 840122
    Miami, Florida 33173, United States
  • Chiesi Clinical Trial Site 840352
    Miami, Florida 33173, United States
  • Chiesi Clinical Trial Site 840235
    Miami, Florida 33174, United States
  • Chiesi Clinical Trial Site 840360
    Miami, Florida 33174, United States
  • Chiesi Clinical Trial Site 840381
    Miami, Florida 33174, United States
  • Chiesi Clinical Trial Site 840243
    Miami, Florida 33175, United States
  • Chiesi Clinical Trial Site 840244
    Miami, Florida 33175, United States
  • Chiesi Clinical Trial Site 840257
    Miami, Florida 33175, United States
  • Chiesi Clinical Trial Site 840380
    Miami, Florida 33175, United States
  • Chiesi Clinical Trial Site 840382
    Miami, Florida 33175, United States
  • Chiesi Clinical Trial Site 840367
    Miami, Florida 33176, United States
  • Chiesi Clinical Trial Site 840162
    Miami, Florida 33186, United States
  • Chiesi Clinical Trial Site 840166
    Miami, Florida 33186, United States
  • Chiesi Clinical Trial Site 840370
    Miami, Florida 33186, United States
  • Chiesi Clinical Trial Site 840392
    Miami, Florida 33186, United States
  • Chiesi Clinical Trial Site 840319
    Miami Beach, Florida 33141, United States
  • Chiesi Clinical Trial Site 840328
    Miami Lakes, Florida 33014, United States
  • Chiesi Clinical Trial Site 840378
    Miami Lakes, Florida 33014, United States
  • Chiesi Clinical Trial Site 840288
    Miami Lakes, Florida 33016, United States

Showing the first 100 of 436 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312. Epub 2012 Jun 27. PubMed 22743675 ↗
  • Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006 Feb;27(2):397-412. doi: 10.1183/09031936.06.00025805. No abstract available. PubMed 16452599 ↗
  • Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De Leon FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0. PubMed 23245604 ↗
  • Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442. doi: 10.1371/journal.pmed.0030442. PubMed 17132052 ↗
  • Montes de Oca M, Perez-Padilla R, Talamo C, Halbert RJ, Moreno D, Lopez MV, Muino A, Jose Roberto BJ, Valdivia G, Pertuze J, Ana Maria BM; PLATINO Team. Acute bronchodilator responsiveness in subjects with and without airflow obstruction in five Latin American cities: the PLATINO study. Pulm Pharmacol Ther. 2010 Feb;23(1):29-35. doi: 10.1016/j.pupt.2009.09.005. Epub 2009 Oct 8. PubMed 19818867 ↗
  • Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999 Jul;54(7):581-6. doi: 10.1136/thx.54.7.581. PubMed 10377201 ↗
  • Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648-54. doi: 10.1183/09031936.00102509. PubMed 19720809 ↗
  • Lane DC, Stemkowski S, Stanford RH, Tao Z. Initiation of Triple Therapy with Multiple Inhalers in Chronic Obstructive Pulmonary Disease: An Analysis of Treatment Patterns from a U.S. Retrospective Database Study. J Manag Care Spec Pharm. 2018 Nov;24(11):1165-1172. doi: 10.18553/jmcp.2018.24.11.1165. PubMed 30362922 ↗
  • Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18. PubMed 29668352 ↗
  • Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Oct 15;180(8):741-50. doi: 10.1164/rccm.200904-0492OC. Epub 2009 Jul 30. PubMed 19644045 ↗
  • Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan;106(1):91-101. doi: 10.1016/j.rmed.2011.09.002. Epub 2011 Oct 29. PubMed 22040533 ↗
  • Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD; Korean Academy of Tuberculosis and Respiratory Diseases study group; Korea Chronic Obstructive Pulmonary Disease study group. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2012 Mar;106(3):382-9. doi: 10.1016/j.rmed.2011.09.004. Epub 2011 Oct 4. PubMed 21975275 ↗
  • Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446. doi: 10.1164/rccm.201703-0449OC. PubMed 28375647 ↗
  • Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018 Oct;6(10):747-758. doi: 10.1016/S2213-2600(18)30327-8. Epub 2018 Sep 16. PubMed 30232048 ↗
  • Singh D, Papi A, Corradi M, Pavlisova I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016 Sep 3;388(10048):963-73. doi: 10.1016/S0140-6736(16)31354-X. Epub 2016 Sep 1. PubMed 27598678 ↗
  • Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017 May 13;389(10082):1919-1929. doi: 10.1016/S0140-6736(17)30188-5. Epub 2017 Apr 3. PubMed 28385353 ↗
  • Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. PubMed 29429593 ↗
  • Wedzicha JA, Singh D, Vestbo J, Paggiaro PL, Jones PW, Bonnet-Gonod F, Cohuet G, Corradi M, Vezzoli S, Petruzzelli S, Agusti A; FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014 Aug;108(8):1153-62. doi: 10.1016/j.rmed.2014.05.013. Epub 2014 Jun 6. PubMed 24953015 ↗
  • Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT) scores. BMC Pulm Med. 2011 Aug 11;11:42. doi: 10.1186/1471-2466-11-42. PubMed 21835018 ↗
  • Mullerova H, Dransfield MT, Thomashow B, Jones PW, Rennard S, Karlsson N, Fageras M, Metzdorf N, Petruzzelli S, Rommes J, Sciurba FC, Tabberer M, Merrill D, Tal-Singer R. Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test. Am J Respir Crit Care Med. 2020 May 1;201(9):1058-1067. doi: 10.1164/rccm.201907-1369PP. No abstract available. PubMed 31815521 ↗
  • Kon SS, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, Haselden BM, Polkey MI, Man WD. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014 Mar;2(3):195-203. doi: 10.1016/S2213-2600(14)70001-3. Epub 2014 Feb 4. PubMed 24621681 ↗
  • Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available. PubMed 16055882 ↗
  • Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, van der Grinten C, Gustafsson P, Jensen R, Macintyre N, McKay RT, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of lung function testing: the authors' replies to readers' comments. Eur Respir J. 2010 Dec;36(6):1496-8. doi: 10.1183/09031936.00130010. No abstract available. PubMed 21119213 ↗
  • Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196-204. doi: 10.7326/0003-4819-106-2-196. PubMed 3492164 ↗
  • Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22. doi: 10.1164/ajrccm.157.5.9709032. PubMed 9603117 ↗
  • Jones PW. St. George's Respiratory Questionnaire: MCID. COPD. 2005 Mar;2(1):75-9. doi: 10.1081/copd-200050513. PubMed 17136966 ↗
  • Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient. Respir Med. 2005 Dec;99 Suppl B:S11-8. doi: 10.1016/j.rmed.2005.09.011. Epub 2005 Oct 19. PubMed 16236492 ↗
  • Jones PW, Gelhorn H, Wilson H, Karlsson N, Menjoge S, Mullerova H, Rennard SI, Tal-Singer R, Merrill D, Tabberer M. Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire. Chronic Obstr Pulm Dis. 2017 Mar 2;4(2):124-131. doi: 10.15326/jcopdf.4.2.2017.0130. PubMed 28848921 ↗
  • Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004 Jul;126(1):213-9. doi: 10.1378/chest.126.1.213. PubMed 15249465 ↗
  • Ellepola AN, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis. 2001 Jul;7(4):211-6. PubMed 11575870 ↗
  • Roger JH, Bratton DJ, Mayer B, Abellan JJ, Keene ON. Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment. Pharm Stat. 2019 Jan;18(1):85-95. doi: 10.1002/pst.1910. Epub 2018 Nov 8. PubMed 30406948 ↗
  • Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002 Mar;35(3):716-21. doi: 10.1053/jhep.2002.31250. PubMed 11870389 ↗
  • Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY; International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011 Apr;33(7):739-47. doi: 10.1111/j.1365-2036.2011.04590.x. Epub 2011 Feb 9. PubMed 21306407 ↗

Individual participant data

Plan to share: Yes

Access criteria: Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website.

Data sharing details ↗ · www.chiesi.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jan 2026, 44 months.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 44 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2020
First posted
Mar 25, 2020
StartActual
Apr 27, 2022
Primary completionActual
Jan 12, 2026
CompletionActual
Jan 12, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04320342
Responsible party
Sponsor
First posted
Mar 25, 2020
Start date
Apr 27, 2022
Primary completion
Jan 12, 2026
Completion
Jan 12, 2026
Last update
Sep 21, 2026

Study contacts

Thomas Siler, MD
principal investigator · Midwest Chest Consultants

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion